-
Electronic (PDF)
-
1 - 5 Users
-
1 - 10 Users
-
1 - 15 Users
Growth Factors (Blood And Tissue) - Global Business Strategic Report
Global Industry Analysts, Inc, May 2012, Pages: 579
This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following Growth Factor Types: Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), and Tissue Growth Factors. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 90 companies including many key and niche players such as Alseres Pharmaceuticals, Inc., Amgen, Inc., Bayer HealthCare Pharmaceuticals Inc., BioMimetic Therapeutics, Inc., Biopharm GmbH, Bolder Biotechnology, Inc., Ceregene Inc., FibroGen Inc., FzioMed Inc., Novo Nordisk A/S, Reliance GeneMedix Plc, Johnson & Johnson, Janssen, Inc., Lonza Group, Maxygen, Inc., Merck Serono International S.A., NsGene A/S, PeproTech, Inc., Rentschler Biotechnologie GmbH, F. Hoffmann-La Roche Ltd., Chugai Pharmaceutical Co. Ltd., Genentech, Inc., Shantha Biotechnics, Scil Proteins GmbH, and Wockhardt Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
GROWTH FACTORS (BLOOD AND TISSUE)
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Blood Growth Factors I-4
Erythropoietins I-4
Colony Stimulating Factors I-4
Interferons I-4
Interleukins I-4
Tissue Growth Factors I-4
II. Executive Summary
1. INTRODUCTION II-1
Growth Factors: A Preface II-1
Growth Factors: Their Role and Related Applications II-1
Growth Factors: Adding a New Dimension II-1
Growth Factors: Classification Based on Activity II-1
Recent Trends & Developments II-2
Recombinant Human Erythropoietin: Gradually Gaining Dominance II-2
Leading EPO Drugs Worldwide II-2
Market Comparison of Erythropoietin-Based Drugs in America
and European Union II-2
Patent Expiries of Major Biopharmaceutical Drugs: 2001-2007 II-3
Patent Expiries of Biopharmaceuticals in Developed Regions -
Europe and United States II-4
2. MARKET DYNAMICS II-5
Major Companies Impacted by Patent Expiries II-5
Patent Expiries Fuel Competition and Sales II-5
Side Effects - Still a Concern II-5
CDER- A Regulatory Review Authority for Growth Factors II-5
Innovative Delivery System Shows Potential for Accelerating
Use of Growth Factors II-6
Cytokines- Vital Growth Propellers for the Future of New Drugs II-6
Brain Derived Neurotrophic Factor (BDNF) Finds Increased
Application II-6
Age-Related Diseases - Their Influence on Effective Therapies II-6
Mimetic Growth Factors - Exhibiting Promising Potential II-7
India - At the Center Stage II-7
3. INDUSTRY ISSUES II-8
Development of Cost Effective Methods - Need of the Hour II-8
Influence of Neurotrophic Factors on Brain Cell Development II-8
Combination of Interferons and Ribavirin Develops More Anemia
Cases II-8
4. GROWTH FACTORS - AN OVERVIEW II-9
Blood Growth Factors II-9
Erythropoietins II-9
Types of Erythropoietins II-10
Epoetin II-10
Darbepoetin II-10
Aranesp® II-10
Aranesp Vs. Other EPOs II-10
Recombinant Human EPO (rHuEPO) II-10
Colony Stimulating Factors II-11
Granulocyte-Colony Stimulating Factor II-11
Granulocyte Macrophage-Colony Stimulating Factor II-11
Other Colony Stimulating Factors II-11
Macrophage Colony Stimulating Factor (M-CSF) II-12
Key Functions of M-CSF II-12
Side-Effects of Colony-Stimulating Factors II-12
Interferons II-12
Types of Interferons II-12
Interferon-gamma II-13
1a and 1b: Two Key Biochemical Forms of Interferon-ß II-13
PEG-Intron II-13
Types of Interferons II-14
Interleukins II-14
Types of Interleukins II-14
Tissue Growth Factors II-15
Wound Healing Growth Factors II-15
Neurotrophic Growth Factors II-15
Nerve Growth Factor II-16
Vascular Endothelial Growth Factor (VEGF) II-16
Fibroblast Growth Factor (FGF) II-16
Insulin-Like Growth Factor-I (IGF-I) II-16
Insulin-Like Growth Factor-II (IGF-II) II-16
Tissue Growth Factors: Classification Based on Key Source
and Principal Activity II-17
Platelet - Derived Growth Factors in Wound Healing II-17
Thrombopoietin (TPO) II-17
Growth Factors: Their Mode of Action in Tissue Repair II-18
Angiogenesis: Their Role in Wound Healing II-18
Angiogenesis As an Alternative for Cardiac Stents II-18
Applications of Growth Factors II-18
Growth Factors: Site/Course of Action and Applications II-19
5. RESEARCH AND DEVELOPMENT HIGHLIGHTS A RECENT PAST REVIEW II-20
Maxygen Updates on Factor VII Program II-20
Evaluation of Extended Dosing Schedule of PROCRIT® II-20
PROCRIT® - A Better Option II-20
Nerve Growth Factor Shows Promising Potential Against Diabetes II-20
Cytokines and GM-CSF Found to be Closely Interlinked II-21
GM-CSF Enhances Rate of Survival in Neonates II-21
rG-CSF Well Tolerated in Pneumonia and Severe Sepsis Patients II-22
rG-CSF- Their Influence on Preterm Infants with Sepsis II-22
Serum Macrophage Colony Stimulating Growth Factors Associated
with Thrombocyte and Monocyte II-22
Src Pathway Inactivation in Kit Impairs Blood Cell Growth and
Proliferation II-22
Cole Eye Institute Offers TIMP-3 Mechanism for Preventing
Abnormal Growth of Blood Vessels II-23
Effect of Brain Derived Neurotrophic Factor on Retinal Cells II-23
Orcel™ Exhibits High Growth Factor for Wound Healing and
Cardiovascular Applications II-24
Drug Combination of Macrophage Colony Stimulating Factor Shows
Successful Tolerance Levels II-24
Neotrofin™ Triggers Neurotrophic Factors II-24
G-CSF Shows Capability for Promoting Neutrophil Production II-25
Insulin-like Growth Factor-1 (IGF) Gene Transfer Accelerates
Wound Healing Process II-25
Hepatocyte Growth Factors - Exhibiting Dual Role II-26
Cortex Pharmaceuticals Ampakines® Promotes Expression of
Neurotrophin II-26
Granulocyte Colony Stimulating Factor Finds Application in
Treating Neonates II-26
Cerebrolysin Promotes Cognition II-26
6. BREAKTHROUGHS - A RECENT PAST REVIEW II-27
Novel Set of Human Cytokines Unveiled II-27
IGFBP-3 and its Potential to Ward Off Gastric Cancer II-27
Bone Morphogenic Proteins Show Potential for Musculoskeletal
Regeneration II-27
Growth Factors - Their Role in Preventing Heart Stroke II-27
Growth Factor Proteins Show Promising Results for Treating Cancer II-27
Neurotrophic Growth Factor - Primarily Responsible for Loss of
Vision II-28
Redox-Active Grape Seed Exhibits Favorable Properties for
Dermal Wound Healing II-28
Role of Brain-Derived Neurotrophic Factor on Memory II-28
Nerve Growth Factor Found to Enhance Barium Current and
Insulin Secretion II-28
Lipid Peroxidation May be Associated with Wound Healing II-29
Genentech Inc Unveils Molecule for Stimulating Growth of Blood
Vessels II-29
Connective Tissue Growth Factor Found to Promote Lung Fibroblast II-29
Influence of Insulin-Like Growth Factor on Growth II-30
Regeneron Discovers Angiopoietins Targeted at Blood Vessel
Growth and Repair II-30
Environment and Insulin-Like Growth Factors Stimulate Risk of
Cancer II-30
Cocktail of Neurotrophic Factors Promotes Regeneration of Torn
Nerves II-30
Growth Factors Administration to Stimulate Tissue Repair II-31
Cytokine - Their Role in Combating Hepatitis C Virus II-31
Axokine® Yields Favorable Results Against Obesity II-31
Cell Genesys Unveils GDNF Gene Therapy Targeted Against
Parkinson's Disease II-31
7. PRODUCT INTRODUCTIONS/INNOVATIONS II-32
Sandoz Unveils Zarzio II-32
Wockhardt Launches Three Biotechnology Products II-32
Extavia® Receives Approval from European Commission II-32
Amgen Bags EC Approval on Use of Aranesp(R) in Paediatric
Patients II-33
Hospira Receives EC Approval on Retacrit II-33
Tercica Receives FDA Approval For Increlex II-33
Ventria Bioscience Introduces Lacromin II-33
Dragon Pharmaceuticals Bags Market Approval from Chinese SDA II-33
DPI Receives Approvals for Erythropoietin in Three New Markets II-34
Wockhardt Introduces Wepox Recombinant Erythropoietin Drug II-34
Shanta Biotechnics Unveils Shanferon II-34
SkinMedica Unveils TNS Recovery Complex™ Gel II-34
CellGenix Unveils Cytokines for Cell Applications II-34
Cel-Sci Corporation Develops Multikine II-35
Wockhardt Limited Unveils EPOX™ II-35
8. RECENT INDUSTRY ACTIVITY II-36
Soluble Systems Collaborates with LifeNet Health's Subsidiary
to Introduce TheraSkin™ II-36
GlaxoSmithKline and JCR Pharmaceuticals Enters into Partnership II-36
Sanofi Takes Over Shantha Biotech II-36
Kaken Pharmaceutical Enters into Licensing Agreement with
Olympus Corporation II-37
9. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER II-38
Biovitrum and Amgen Sign Agreement II-38
Merck Establishes Production Unit II-38
Eli Lilly and Company Acquires ImClone Systems II-38
GeneMedix Changes Name to Reliance GeneMedix II-39
FDA Approves Label Expansion for VIDAZA II-39
Pfizer Inks Exclusive Global Licensing Agreement with Scil
Technology II-39
ZGEN Initiates Ph II Trial of Interleukin 21 II-39
FzioMed Bags Health Canada Approval on Oxiplex® II-40
NsGene A/S Implants Encapsulated Cell in Patients II-40
Reliance Life Sciences Takes Over Genemedix II-40
Fraunhofer Institute Introduces First Interferon Beta 1a to
Treat Multiple Sclerosis II-40
Shanghai Wanxing Inks Export Deal for Recombinant Human
Interferon II-41
Hemispherx Enters into Distribution Agreement with Armada II-41
Bayer Establishes US Pharmaceuticals Subsidiary II-41
Merck Inks Agreement with Bristol-Myers Squibb and ImClone II-41
CoGenesys Signs Global Licensing Agreement with Vegenics II-42
InterMune Inks New Supply Deal with Boehringer Ingelheim II-42
Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals II-42
Cambrex Divests Bioproducts and Biopharma Subsidiaries II-43
Dragon Divests EPO Business II-43
Caregene and Genzyme Forms Partnership to Develop Cere-120 II-43
NsGene to Undertake Phase Ib Clinical Trial of NsG0202 II-44
Roche Receives European approval for NeoRecormon II-44
Bolder Receives Two U.S. Patents for Hematopoietic Factors II-44
RLS to Initiate Clinical Trials of Erythropoietin II-44
InterMune Drops Phase III trial of Interferon II-44
Chugai to Conduct Additional Trial on Epogin® II-45
Merck KGaA Acquires Serono Labs II-45
CytoPharm Acquires Low-Dose Interferon License from Amarillo
Biosciences II-45
Hospira Signs Agreements with STADA and BIOCEUTICALS for
Erythropoietin II-45
Biocon Bags GEAC Approval to Conduct Clinical Trial of
Granulocyte Colony Stimulating Factor II-46
SII to Conduct Clinical Trials of Rdna Products II-46
Claris to Construct Production Facility for EOP II-46
Mayne and Pliva to End Collaboration on Erythropoietin
Development II-46
GeneMedix Collaborates with CJ Corp. II-47
FzioMed and USC Enter into Licensing Agreement for Oligopeptides II-47
AnGes MG Enters Into An Agreement with Vical II-47
Corautus and BIA Sign Agreement for VEGF-2 plasmid DNA II-47
Dragon Pharmaceuticals Acquires Oriental Wave II-48
Insmed Enters into Exclusive Agreement with UCSF for IGF-1 Series II-48
Amrad and Ludwig Institute Jointly Focus on the Development of
VEGF-B II-48
GeneMedix Restructures Business II-48
pSivida Limited Collaborates with Ian Wark Research Institute II-48
Amgen Acquires Tularik II-49
BMPI Signs up Luitpold Pharmaceuticals for FDA Approved GEM 21S™ II-49
Chugai and Roche Expand Drug Research Synergies II-49
Dragon Pharmaceuticals to Construct New Production Facility II-49
FibroGen Signs Contract with Yamanouchi for Licensing EPO
Small Molecule II-49
Insmed and Tzamal Pharma Sign Agreement for Promoting SomatoKine II-50
Maxygen and Rentschler Enter into a Contract for G-CSF II-50
Maxygen Signs Agreement with Biovitrum for Manufacturing Beta
Interferon II-50
Dragon Pharmaceuticals Signs Agreement with Zhongkai II-50
Dragon Pharmaceuticals Enters into Definitive Agreement with
Oriental Wave II-50
Zymogenetics Bags US FDA Clearance II-51
Ceregene Bags Patent II-51
10. FOCUS ON SELECT GLOBAL PLAYERS II-52
Alseres Pharmaceuticals, Inc. (USA) II-52
Amgen, Inc. (USA) II-52
Bayer HealthCare Pharmaceuticals, Inc. (USA) II-52
BioMimetic Therapeutics, Inc. (USA) II-52
Biopharm GmbH (Germany) II-53
Bolder Biotechnology, Inc. (USA) II-53
Ceregene, Inc. (USA) II-53
FibroGen, Inc. (USA) II-53
FzioMed, Inc. (USA) II-54
Genzyme Corporation (USA) II-54
Novo Nordisk A/S (Denmark) II-54
Reliance GeneMedix Plc. (UK) II-55
Johnson & Johnson (USA) II-55
Janssen, Inc. (Canada) II-55
Lonza Group (Switzerland) II-56
Maxygen, Inc. (USA) II-56
Merck Serono International S.A. (Switzerland) II-56
NsGene A/S (Denmark) II-57
PeproTech, Inc. (USA) II-57
Rentschler Biotechnologie GmbH (Germany) II-57
F. Hoffmann-La Roche Ltd (Switzerland) II-57
Chugai Pharmaceutical Co. Ltd. (Japan) II-58
Genentech, Inc. (USA) II-58
Shantha Biotechnics (India) II-58
Scil Proteins GmbH (Germany) II-58
Wockhardt Ltd. (India) II-59
11. GLOBAL MARKET PERSPECTIVE II-60
Table 1: World Recent Past, Current & Future Analysis for
Growth Factors (Blood and Tissue) by Geographic Region - US,
Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2009 through 2017(includes corresponding Graph/Chart) II-60
Table 2: World Historic Review for Growth Factors (Blood and
Tissue) by Geographic Region - US, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-61
Table 3: World 15-Year Perspective for Growth Factors (Blood
and Tissue) by Geographic Region - Percentage Breakdown of
Value Sales for US, Japan, Europe, and Rest of World Markets
for Years 2003, 2011 & 2017 (includes corresponding
Graph/Chart) II-62
Table 4: World Recent Past, Current & Future Analysis for
Blood Growth Factors by Geographic Region - US, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through
2017(includes corresponding Graph/Chart) II-63
Table 5: World Historic Review for Blood Growth Factors by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 003 through 2008 (includes corresponding
Graph/Chart) II-64
Table 6: World 15-Year Perspective for Blood Growth Factors by
Geographic Region - Percentage Breakdown of Value Sales for
US, Japan, Europe, and Rest of World Markets for Years 2003,
2011 & 2017(includes corresponding Graph/Chart) II-65
Table 7: World Recent Past, Current & Future Analysis for
Blood Growth Factors by Type - Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) II-66
Table 8: World Historic Review for Blood Growth Factors by
Type - Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) II-67
Table 9: World 15-Year Perspective for Blood Growth Factors by
Type - Percentage Breakdown of Value Sales for
Erythropoietins, Colony Stimulating Factors, Interferons and
Interleukins Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) II-68
Table 10: World Recent Past, Current & Future Analysis for
Erythropoietins by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017(includes
corresponding Graph/Chart) II-69
Table 11: World Historic Review for Erythropoietins by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-70
Table 12: World 15-Year Perspective for Erythropoietins by
Geographic Region - Percentage Breakdown of Value Sales for
US, Japan, Europe, and Rest of World Markets for Years 2003,
2011 & 2017(includes corresponding Graph/Chart) II-71
Table 13: World Recent Past, Current & Future Analysis for
Colony Stimulating Factors by Geographic Region - US, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017(includes corresponding Graph/Chart) II-72
Table 14: World Historic Review for Colony Stimulating Factors
by Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-73
Table 15: World 15-Year Perspective for Colony Stimulating
Factors by Geographic Region - Percentage Breakdown of Value
Sales for US, Japan, Europe, and Rest of World Markets for
Years 2003, 2011 & 2017 (includes corresponding Graph/Chart) II-74
Table 16: World Recent Past, Current & Future Analysis for
Interferons as Blood Growth Factors by Geographic Region - US,
Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2009 through 2017(includes corresponding Graph/Chart) II-75
Table 17: World Historic Review for Interferons as Blood
Growth Factors by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-76
Table 18: World 15-Year Perspective for Interferons as Blood
Growth Factors by Geographic Region - Percentage Breakdown of
Value Sales for US, Japan, Europe, and Rest of World Markets
for Years 2003, 2011 & 2017 (includes corresponding
Graph/Chart) II-77
Table 19: World Recent Past, Current & Future Analysis for
Interleukins as Blood Growth Factors by Geographic Region -
US, Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2009 through 2017(includes corresponding Graph/Chart) II-78
Table 20: World Historic Review for Interleukins as Blood
Growth Factors by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-79
Table 21: World 15-Year Perspective for Interleukins as Blood
Growth Factors by Geographic Region - Percentage Breakdown of
Value Sales for US, Japan, Europe, and Rest of World Markets
for Years 2003, 2011 & 2017 (includes corresponding
Graph/Chart) II-80
Table 22: World Recent Past, Current & Future Analysis for
Tissue Growth Factors by Geographic Region - US, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017(includes corresponding Graph/Chart) II-81
Table 23: World Historic Review for Tissue Growth Factors by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-82
Table 24: World 15-Year Perspective for Tissue Growth Factors
by Geographic Region - Percentage Breakdown of Value Sales for
US, Japan, Europe, and Rest of World Markets for Years 2003,
2011 & 2017 (includes corresponding Graph/Chart) II-83
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Leading EPO Drugs in the US III-1
B.Market Analytics III-2
Table 25: The US Recent Past, Current & Future Analysis for
Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-2
Table 26: The US Historic Review for Growth Factors by Type -
Blood Growth Factors (Erythropoietins, Colony Stimulating
Factors, Interferons and Interleukins) and Tissue Growth
Factors Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) III-3
Table 27: The US 15-Year Perspective for Growth Factors by
Type - Percentage Breakdown of Value Sales for Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors
Markets for Years 2003, 2011 & 2017 (includes corresponding
Graph/Chart) III-4
2. JAPAN III-5
A.Market Analysis III-5
Erythropoietin Market III-5
Leading EPO Drugs in Japan III-5
Market Scenario for Biotech Products III-5
Biotech Market Backed by Public Assistance III-5
B.Market Analytics III-6
Table 28: Japanese Recent Past, Current & Future Analysis
for Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-6
Table 29: Japanese Historic Review for Growth Factors by
Type - Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and
Tissue Growth Factors Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-7
Table 30: Japanese 15-Year Perspective for Growth Factors by
Type - Percentage Breakdown of Value Sales for Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors
Markets for Years 2003, 2011 & 2017(includes corresponding
Graph/Chart) III-8
3. EUROPE III-9
A.Market Analysis III-9
Erythropoietin Market III-9
Leading EPO Drugs in Europe III-9
B.Market Analytics III-10
Table 31: European Recent Past, Current & Future Analysis
for Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-10
Table 32: European Historic Review for Growth Factors by
Type - Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and
Tissue Growth Factors Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-11
Table 33: European 15-Year Perspective for Growth Factors by
Type - Percentage Breakdown of Value Sales for Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors
Markets for Years 2003, 2011 & 2017 (includes corresponding
Graph/Chart) III-12
4. REST OF WORLD III-13
A.Market Analysis III-13
An Overview of Indian Market III-13
Erythropoietin III-13
G-CSF Market III-13
Interferon III-13
B.Market Analytics III-14
Table 34: Rest of World Recent Past, Current & Future
Analysis for Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-14
Table 35: Rest of World Historic Review for Growth Factors
by Type - Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and
Tissue Growth Factors Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-15
Table 36: Rest of World 15-Year Perspective for Growth
Factors by Type - Percentage Breakdown of Value Sales for
Blood Growth Factors (Erythropoietins, Colony Stimulating
Factors, Interferons and Interleukins) and Tissue Growth
Factors Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-16
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 90 (including Divisions/Subsidiaries - 100)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 54
Canada 3
Japan 5
Europe 21
Germany 11
The United Kingdom 2
Rest of Europe 8
Asia-Pacific (Excluding Japan) 13
Middle East 4
------------------------------------------
Growth factors (blood and tissue) offer immense potential for applications in diverse areas and are presently finding a firm foothold in the bio-pharmaceutical market. Wound healing represents a key application area for growth factors. Growth factors are presently used as potential therapeutic agents to deal with critical conditions, such as Ranulocytopenia, Leukemia, Aplastic anaemia, Bone marrow transplantation, and Myelodysplastic syndrome. Blood growth factors are gaining immense popularity, owing to several new therapeutic applications, such as colony stimulating factors finding a role in neutropenia prevention and treatment. Brain Derived Neurotrophic Factor (BDNF) is emerging as an efficient alternative to VEGF and FGFs administered to ischemic patients for neo-angiogenesis and neo-vascularization. Also vital for cancer therapies and regenerative medicine, BDNFs are emerging as the preferred therapeutic proteins for organ specific angiogenesis. In the coming years, the increase in the incidence of age-related diseases is expected to be a significant driver for the growth factors market.
An important factor boosting the growth potential of the market is the patent expiries of major branded drugs, such as Neupogen, Avonex, Epogen, Intron and Roferon. Expiration of major patents over the years for Erythropoietins and Colony Stimulating Factors in the US and the Europe has opened the doors for generic drugs in these regions. In Asia, Latin America, and Eastern Europe, the generic products have already been developed and marketed. As such, Erythropoietin market is very profitable due to low marketing and distribution costs. This is due to the distinct patient population and limited distribution outlets. In an untiring fight against diseases, growth factors have achieved much success over the recent years. However, safety still remains a concern due to a considerable amount of unaddressed side effects subsisting in the marketed blood growth factors. As such, development centers are busy finding new processes and formulations to enhance product characteristics and benefits of blood growth factor treatment, while minimizing side effects.
The US represents the largest regional market for growth factors worldwide, as stated by the new market research report on Growth Factors (Blood and Tissue). Europe trails behind the US, which is also the fastest growing market for growth factors. Japanese market is forecast to post a compounded annual growth rate of close to 4.3% during the analysis period. Segment-wise, Erythropoietins and Interferons are the two largest markets in the global growth factors market. The growing demand for recombinant erythropoietin for their application in chemotherapy-induced anemia is an important growth booster in the blood growth factors market.
Human recombinant technologies have triggered the growth factors market to greater heights. With the future projected to show promising growth in drug discovery and research, there is an urgent need to develop potential innovative delivery systems that would expand the acceptance of growth factors as a viable and effective therapy. In addition, the successful development of mimetic growth factors may prove to be a suitable alternative to recombinant growth factors. In years to come, the bio-market may soon witness a new era for mimetic growth factors, characterized by attributes such as higher rate of efficiency, and lower production cost associated.
Global Industry Analysts ©
Sample List of Companies
- Alseres Pharmaceuticals, Inc. (USA)
- Amgen, Inc. (USA)
- Bayer HealthCare Pharmaceuticals Inc. (USA)
- BioMimetic Therapeutics, Inc. (USA)
- Biopharm GmbH (Germany)
- Bolder Biotechnology, Inc. (USA)
- Ceregene, Inc. (USA)
- FibroGen, Inc. (USA)
- FzioMed, Inc. (USA)
- Novo Nordisk A/S (Denmark)
- Reliance GeneMedix Plc. (UK)
- Insmed, Inc. (USA)
- Johnson & Johnson (USA)
- Janssen-Ortho, Inc. (Canada)
- Lonza Group (Switzerland)
- Maxygen, Inc. (USA)
- Merck Serono International S.A. (Switzerland)
- NsGene A/S (Denmark)
- PeproTech, Inc. (USA)
- Rentschler Biotechnologie GmbH (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Chugai Pharmaceutical Co. Ltd. (Japan)
- Genentech, Inc. (USA)
- Shantha Biotechnics (India)
- Scil Proteins GmbH (Germany)
- Wockhardt Ltd. (India)
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
